Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Young Min Cho (Cho YM), Rhonda D. Wideman (Wideman RD), Timothy J. Kieffer (Kieffer TJ)
Endocrinol Metab. 2013;28(4):262-274.   Published online 2013 Dec 12     DOI:
Citations to this article as recorded by Crossref logo
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Hun Jee Choe, Young Min Cho
Endocrinology and Metabolism.2021; 36(1): 22.     CrossRef
Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
Xingchun Wang, Bingwei Ma, Jiaqi Chen, Hui You, Chunjun Sheng, Peng Yang, Shen Qu, Vito Angelo Giagulli
International Journal of Endocrinology.2021; 2021: 1.     CrossRef
Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin
Zeinab A. Saad, Dina M. Khodeer, Sawsan A. Zaitone, Amal A.M. Ahmed, Yasser M. Moustafa
Life Sciences.2020; 253: 117725.     CrossRef
Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
Shan Li, Xiaoman Wang, Jielei Zhang, Jingyi Li, Xiaogang Liu, Yuanyuan Ma, Chao Han, Lixia Zhang, Lili Zheng
Brazilian Journal of Medical and Biological Research.2018;[Epub]     CrossRef
Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis
Se Hee Min, Jeong-Hwa Yoon, Seokyung Hahn, Young Min Cho
Journal of Diabetes Investigation.2018; 9(4): 893.     CrossRef
What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus
Wing B. Chan, Andrea Luk, Wing S. Chow, Vincent T.F. Yeung
Journal of Diabetes.2017; 9(6): 562.     CrossRef
Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
L. Østergaard, Christian S. Frandsen, S. Madsbad
Expert Review of Clinical Pharmacology.2016; 9(2): 241.     CrossRef
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
Johan Jendle, George Grunberger, Thomas Blevins, Francesco Giorgino, Ryan T. Hietpas, Fady T. Botros
Diabetes/Metabolism Research and Reviews.2016; 32(8): 776.     CrossRef
Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?
Guojing Luo, Hong Liu, Hongyun Lu
British Journal of Clinical Pharmacology.2016; 81(1): 78.     CrossRef
Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?
Sten Madsbad
Journal of Diabetes and its Complications.2016; 30(2): 374.     CrossRef
Risk assessment and management of post-transplant diabetes mellitus
Eugene Han, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
Metabolism.2016; 65(10): 1559.     CrossRef
Recent advances in oral delivery of peptide hormones
Pegah Varamini, Istvan Toth
Expert Opinion on Drug Delivery.2016; 13(4): 507.     CrossRef
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
PLOS ONE.2016; 11(12): e0166913.     CrossRef
Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
Sten Madsbad
Diabetes, Obesity and Metabolism.2016; 18(4): 317.     CrossRef
Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin-1 in the Diabetic Brain
Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236.     CrossRef
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
P. D. Home, P. Shamanna, M. Stewart, F. Yang, M. Miller, C. Perry, M. C. Carr
Diabetes, Obesity and Metabolism.2015; 17(2): 179.     CrossRef
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Jaime A. Davidson
Postgraduate Medicine.2015; 127(8): 827.     CrossRef
GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease
Jia Liu, Guang Wang, Yumei Jia, Yuan Xu
Diabetes/Metabolism Research and Reviews.2015; 31(4): 329.     CrossRef
Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in K orean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase
M. K. Kim, E.‐J. Rhee, K. A. Han, A. C. Woo, M.‐K. Lee, B. J. Ku, C. H. Chung, K.‐A. Kim, H. W. Lee, I. B. Park, J. Y. Park, H. C. Chul Jang, K. S. Park, W. I. Jang, B. Y. Cha
Diabetes, Obesity and Metabolism.2015; 17(3): 309.     CrossRef
Incretin physiology and pathophysiology from an A sian perspective
Young Min Cho
Journal of Diabetes Investigation.2015; 6(5): 495.     CrossRef
Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab J2015;39:74-81)
Antoni Sicras-Mainar, Ruth Navarro-Artieda
Diabetes & Metabolism Journal.2015; 39(2): 173.     CrossRef
Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
Se Hee Min, Young Min Cho
The Journal of Korean Diabetes.2015; 16(4): 252.     CrossRef
Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cells
Min Joo Kim, Ok Kyong Choi, Kyung Sil Chae, Hakmo Lee, Sung Soo Chung, Dong-Sik Ham, Ji-Won Kim, Kun-Ho Yoon, Kyong Soo Park, Hye Seung Jung
Islets.2015; 7(5): e1129096.     CrossRef
Glucagon-Like Peptide-1 Increases Mitochondrial Biogenesis and Function in INS-1 Rat Insulinoma Cells
Mi Yeon Kang, Tae Jung Oh, Young Min Cho
Endocrinology and Metabolism.2015; 30(2): 216.     CrossRef
The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells
Hirohisa Onuma, Kouichi Inukai, Atsuko Kitahara, Rie Moriya, Susumu Nishida, Toshiaki Tanaka, Hidenori Katsuta, Kazuto Takahashi, Yoshikazu Sumitani, Toshio Hosaka, Hitoshi Ishida
Biochemical and Biophysical Research Communications.2014; 451(2): 339.     CrossRef
Brief Review of Articles in 'Endocrinology and Metabolism' in 2013
Won-Young Lee
Endocrinology and Metabolism.2014; 29(3): 251.     CrossRef
Cytokines and Hormones That Contribute to the Positive Association between Fat and Bone
Dorit Naot, Jillian Cornish
Frontiers in Endocrinology.2014;[Epub]     CrossRef
Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
Maria Voukali, Irene Kastrinelli, Sapfo Stragalinou, Dimitra Tasiopoulou, Pinelopi Paraskevopoulou, Nicholas Katsilambros, Alexandros Kokkinos, Nicholas Tentolouris, Ioannis Ioannidis
Journal of Diabetes Research.2014; 2014: 1.     CrossRef
The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
Mark F McCarty, James J DiNicolantonio
Open Heart.2014; 1(1): e000103.     CrossRef
Nuevos fármacos antidiabéticos: avanzando hacia el control integral de la diabesidad
J.J. Gorgojo-Martínez
Hipertensión y Riesgo Vascular.2014; 31(2): 45.     CrossRef
Managing Loss of Glycemic Control in Middle-Aged Patients With Diabetes: The Role of GLP-1 Receptor Agonists in Combination-Therapy Regimens
Thomas B. Repas
Journal of Osteopathic Medicine.2014; 114(s52): 14.     CrossRef